Back to Results
First PageMeta Content
Biology / Research / Axel Ullrich / Receptor tyrosine kinase / Tyrosine kinase / Salk Institute for Biological Studies


Kolltan Pharmaceuticals Acquires Xetrios Therapeutics and Exclusive Rights to Salk Institute Patents Related to the TAM Receptor Tyrosine Kinase Family TAM Receptors Are Potentially Important Drug Targets for Oncology, A
Add to Reading List

Document Date: 2014-09-16 06:15:27

Open Document

File Size: 45,51 KB

Share Result on Facebook

City

NEW HAVEN / /

Company

Exclusive Rights / Molecular Neurobiology Laboratory / Xetrios Therapeutics Inc. / IP / Kolltan Pharmaceuticals Kolltan / Kolltan Pharmaceuticals Inc. / Investor Inquiries Kolltan Pharmaceuticals Inc. / /

/

Event

M&A / Business Partnership / FDA Phase / /

Facility

Cancer Biology Institute / Salk Institute / laboratory of Greg Lemke / Yale University / /

IndustryTerm

biopharmaceutical / treatment of cancer / machinery / /

MedicalCondition

tumor / serious diseases / cancer / solid tumors / diseases / infectious diseases / /

Organization

Cancer Biology Institute / Yale Medical School / Department of Pharmacology / Salk Institute for Biological Studies in San Diego / Yale University / Cancer Biology Institute at Yale University / /

Person

Jerry McMahon / Françoise GilotSalk / Pharmacology / Greg Lemke / Joseph Schlessinger / Lawrence C. Fritz / Françoise Gilot-Salk / Carla Rothlin / /

/

Position

Professor and Director / Director / Co-Founder / Chair / and exclusively licensed / President and Chief Executive Officer / Chair / biotech entrepreneur / /

Product

ErbB3 / /

ProvinceOrState

California / Connecticut / /

Technology

drug discovery / /

SocialTag